Skip to main content

Advertisement

SpringerLink
Log in

Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

There is evidence that activated immune-inflammatory and oxidative and nitrosative stress (IO&NS) pathways play a role in the pathophysiology of multiple sclerosis (MS) and depression. This study examines serum levels of interleukin (IL)-1β, IL-4, IL-6, and IL-10; peroxides (LOOH); nitric oxide metabolites (NOx); albumin; ferritin; C-reactive protein (CRP); and tumor necrosis factor (TNF)-β NcoI polymorphism (rs909253) and gadolinium-enhanced magnetic resonance imaging (MRI) scan in MS patients with (n = 42) and without (n = 108) depression and normal controls (n = 249). Depression is scored using the depressive subscale of the Hospital Anxiety and Depression Scale (HADS). The extent of neurological disability is measured using the Expanded Disability Status Scale (EDSS) at the same time of the abovementioned measurements and 5 years earlier. Disease progression is assessed as actual EDSS—EDSS 5 years earlier. Three variables discriminate MS patients with depression from those without depression, i.e., increased IL-6 and lower IL-4 and albumin. Binary logistic regression showed that MS with depression (versus no depression) was characterized by more gastrointestinal symptoms and disease progression, higher serum IL-6, and lower albumin levels. In subjects with MS, the HADS score was significantly predicted by three EDSS symptoms, i.e., pyramidal, gastrointestinal, and visual symptoms. Fifty-eight percent of the variance in the HADS score was predicted by gastrointestinal symptoms, visual symptoms, the TNFB1/B2 genotype, and contrast enhancement (both inversely associated). There were no significant associations between depression in MS and type of MS, duration of illness, age, sex, nicotine dependence, and body mass index. MS with depression is associated with signs of peripheral inflammation, more disability, disease progression, gastrointestinal and visual symptoms, but less contrast enhancement as compared to MS without depression. It is concluded that depression is part of the neurological symptoms of MS and that its expression is primed by peripheral inflammation while acute neuroinflammation and the TNFB1/B2 genotype may be protective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M et al (2014) Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res 2014:961863

    Article  PubMed  PubMed Central  Google Scholar 

  2. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I (2012) Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 45:26–30

    Article  CAS  PubMed  Google Scholar 

  3. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274:48–53

    Article  CAS  PubMed  Google Scholar 

  4. Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:708659

    Article  PubMed  PubMed Central  Google Scholar 

  5. Morris G, Maes M (2013) Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med 11:205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dujmovic I, Mangano K, Pekmezovic T, Quattrocchi C, Mesaros S, Stojsavljevic N, Nicoletti F, Drulovic J (2009) The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 207:101–106

    Article  CAS  PubMed  Google Scholar 

  7. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, Lee SC, Raine CS, Brosnan CF et al (2006) IL-1beta regulates blood–brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 177:5574–5584

    Article  CAS  PubMed  Google Scholar 

  8. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA (1990) Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40:1735–1739

    Article  CAS  PubMed  Google Scholar 

  9. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472

    Article  CAS  PubMed  Google Scholar 

  10. Al-Omaishi J, Bashir R, Gendelman HE (1999) The cellular immunology of multiple sclerosis. J Leukoc Biol 65:444–452

    CAS  PubMed  Google Scholar 

  11. Frei K, Fredrikson S, Fontana A (1991) Link H: interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 31:147–153

    Article  CAS  PubMed  Google Scholar 

  12. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452

    Article  CAS  PubMed  Google Scholar 

  13. Oliveira SR, Kallaur AP, Simão AN, Morimoto HK, Lopes J, Panis C, Petenucci DL, da Silva E et al (2012) Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 321:49–53

    Article  CAS  PubMed  Google Scholar 

  14. Ljubisavljevic S, Stojanovic I, Cvetkovic T, Vojinovic S, Stojanov D, Stojanovic D, Stefanovic N, Pavlovic D (2014) Erythrocytes’ antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation. J Neurol Sci 337:8–13

    Article  CAS  PubMed  Google Scholar 

  15. Gajewski TF, Schell SR, Nau G, Fitch FW (1989) Regulation of T-cell activation: differences among T-cell subsets. Immunol Rev 111:79–110

    Article  CAS  PubMed  Google Scholar 

  16. Murphy KM, Reiner SL (2002) The lineage decisions of helper T cells. Nat Rev Immunol 2:933–944

    Article  CAS  PubMed  Google Scholar 

  17. Imam SA, Guyton MK, Haque A, Vandenbark A, Tyor WR, Ray SK, Banik NL (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190:139–145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Koguchi K, Anderson DE, Yang L, O’Connor KC, Kuchroo VK, Hafler DA (2006) Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med 203:1413–1418

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rodriguez-Sainz Mdel C, Sanchez-Ramon S, de Andres C, Rodriguez-Mahou M, Munoz-Fernandez MA (2002) Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. Eur Cytokine Netw 13:110–114

    PubMed  Google Scholar 

  20. Kallaur AP, Oliveira SR, Simão AN, de Almeida ER, Morimoto HK, Alfieri DF, Pereira WL, Borelli SD et al (2014) Tumor necrosis factor beta NcoI polymorphism is associated with inflammatory and metabolic markers in multiple sclerosis patients. J Neurol Sci 346:156–163

    Article  CAS  PubMed  Google Scholar 

  21. Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, Schininà ME, Di Domenico F et al (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 8:e65184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Encinas JM, Manganas L, Enikolopov G (2005) Nitric oxide and multiple sclerosis. Curr Neurol Neurosci Rep 5:232–238

    Article  CAS  PubMed  Google Scholar 

  23. Skokou M, Soubasi E, Gourzis P (2012) Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol 2012:427102

    Article  PubMed  PubMed Central  Google Scholar 

  24. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C (2014) The link between multiple sclerosis and depression. Nat Rev Neurol 10(9):507–517

    Article  PubMed  Google Scholar 

  25. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J (2011) Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 32:7–24

    CAS  PubMed  Google Scholar 

  26. Vattakatuchery JJ, Rickards H, Cavanna AE (2011) Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci 23:261–276

    Article  CAS  PubMed  Google Scholar 

  27. Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC, Gomes S, Gonçalves MV, da Gama PD et al (2010) Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol 33(6):312–316

    Article  CAS  PubMed  Google Scholar 

  28. Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O et al (2014) A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol 261:2101–2111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zigmond AS, Snaith P (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    Article  CAS  PubMed  Google Scholar 

  30. Norton S, Cosco T, Doyle F, Done J, Sacker A (2013) The Hospital Anxiety and Depression Scale: a meta confirmatory factor analysis. J Psychosom Res 74:74–81

    Article  PubMed  Google Scholar 

  31. Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35:676–692

    Article  CAS  PubMed  Google Scholar 

  32. Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P (2002) Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 27:671–681

    Article  CAS  PubMed  Google Scholar 

  33. Pokryszko-Dragan A, Frydecka I, Kosmaczewska A, Ciszak L, Bilinska M, Gruszka E, Podemski R, Frydecka D (2012) Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis. Clin Neurol Neurosurg 114:1153–1158

    Article  CAS  PubMed  Google Scholar 

  34. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP (2001) Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch Neurol 58:1081–1086

    Article  CAS  PubMed  Google Scholar 

  35. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann Neurol 58:840–846

    Article  PubMed  Google Scholar 

  36. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911

    Article  CAS  PubMed  Google Scholar 

  38. Honarmand K, Feinstein A (2009) Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler 15:1518–1524

    Article  PubMed  Google Scholar 

  39. Navarro-Gonzálvez JA, García-Benayas C, Arenas J (1998) Semiautomated measurement of nitrate in biological fluids. Clin Chem 44:679–681

    PubMed  Google Scholar 

  40. Gonzalez Flecha B, Llesuy S, Boveris A (1991) Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle. Free Radic Biol Med 10:93–100

    Article  CAS  PubMed  Google Scholar 

  41. Repetto M, Reides C, Carretero MLG, Costa M, Griemberg G, Llesuy S (1996) Oxidative stress in blood of HIV infected patients. Clin Chim Acta 255:107–117

    Article  CAS  PubMed  Google Scholar 

  42. Majetschak M, Flohé S, Obertacke U, Schröder J, Staubach K, Nast-Kolb D, Schade FU, Stüber F (1999) Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230:207–214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B, Heesen M (2002) Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol 9:1205–1211

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Delongui F, Carvalho Grion CM, Ehara Watanabe MA, Morimoto HK, Bonametti AM, Maeda Oda JM, Kallaur AP, Matsuo T et al (2011) Association of tumor necrosis factor β genetic polymorphism and sepsis susceptibility. Exp Ther Med 2(2):349–356

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Maes M, Vandewoude M, Scharpé S, De Clercq L, Stevens W, Lepoutre L, Schotte C (1991) Anthropometric and biochemical assessment of the nutritional state in depression: evidence for lower visceral protein plasma levels in depression. J Affect Disord 23:25–33

    Article  CAS  PubMed  Google Scholar 

  46. Maes M (1993) A review on the acute phase response in major depression. Rev Neurosci 4:407–416

    Article  CAS  PubMed  Google Scholar 

  47. Liu Y, Ho RC, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-a) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139(3):230–239

    Article  CAS  PubMed  Google Scholar 

  48. Valkanova V, Ebmeier KP, Allan CL (2013) CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 150:736–744

    Article  CAS  PubMed  Google Scholar 

  49. Koutsouraki E, Hatzifilipou E, Michmizos D, Cotsavasiloglou C, Costa V, Baloyannis S (2011) Increase in interleukin-6 levels is related to depressive phenomena in the acute (relapsing) phase of multiple sclerosis. J Neuropsychiatry Clin Neurosci 23(4):442–448

    Article  CAS  PubMed  Google Scholar 

  50. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813:878–888

    Article  CAS  PubMed  Google Scholar 

  51. Maes M, Anderson G, Kubera M, Berk M (2014) Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets 18:495–512

    Article  CAS  PubMed  Google Scholar 

  52. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 11:1153–1158

    Article  CAS  PubMed  Google Scholar 

  53. Rovira A, Auger C, Alonso J (2013) Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Ther Adv Neurol Disord 6(5):298–310

    Article  PubMed  PubMed Central  Google Scholar 

  54. Cotton F, Weiner HL, Jolesz FA, Guttmann CR (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60(4):640–646

    Article  PubMed  Google Scholar 

  55. Filippi M, Agosta F, Spinelli EG, Rocca MA (2013) Imaging resting state brain function in multiple sclerosis. J Neurol 260:1709–1713

    Article  PubMed  Google Scholar 

  56. Meier DS, Guttmann CR (2003) Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 20:1193–1209

    Article  PubMed  Google Scholar 

  57. Meier DS, Weiner HL, Guttmann CR (2007) MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. Am J Neuroradiol 28:1956–1963

    Article  CAS  PubMed  Google Scholar 

  58. Najjar S, Pearlman DM, Devinsky O, Najjar A, Zagzag D (2013) Neurovascular unit dysfunction with blood–brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation 10:142

    Article  PubMed  PubMed Central  Google Scholar 

  59. Koch MW, Patten S, Berzins S, Zhornitsky S, Greenfield J, Wall W, Metz LM (2015) Depression in multiple sclerosis: a long-term longitudinal study. Mult Scler 21:76–82

    Article  PubMed  Google Scholar 

  60. Alajbegovic A, Loga N, Tiro N, Alajbegovic S, Cindro V, Hozo I (2009) Cognitive and depressive disorders in multiple sclerosis. Acta Clin Croat 48:3–8

    PubMed  Google Scholar 

  61. Koch M, Mostert J, Heerings M, Uyttenboogaart M, De Keyser J (2009) Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study. Eur J Neurol 16:348–352

    Article  CAS  PubMed  Google Scholar 

  62. Askari F, Ghajarzadeh M, Mohammadifar M, Azimi A, Sahraian MA, Owji M (2014) Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. Acta Med Iran 52:889–892

    PubMed  Google Scholar 

  63. Gay MC, Vrignaud P, Garitte C, Meunier C (2010) Predictors of depression in multiple sclerosis patients. Acta Neurol Scand 2010:161–170

    Article  Google Scholar 

  64. Finkelsztejn A, Cristovam Rdo A, Moraes GS, Lopes MG, Silva AV, Garcia MS, Cola CM, Bastiani CE et al (2009) Clinical features of multiple sclerosis in the south of Brazil: a partial analysis. Arq Neuropsiquiatr 67:1071–1075

    Article  PubMed  Google Scholar 

  65. Mattioli F, Bellomi F, Stampatori C, Parrinello G, Capra R (2011) Depression, disability and cognitive impairment in multiple sclerosis: a cross sectional Italian study. Neurol Sci 32:825–832

    Article  PubMed  Google Scholar 

  66. Mendes MF, Tilbery CP, Balsimelli S, Moreira MA, Barão-Cruz AM (2003) Depression in relapsing-remitting multiple sclerosis. Arq Neuropsiquiatr 61:591–595

    Article  PubMed  Google Scholar 

  67. Shen Y, Bai L, Gao Y, Cui F, Tan Z, Tao Y, Sun C, Zhou L (2014) Depressive symptoms in multiple sclerosis from an in vivo study with TBSS. Biomed Res Int 2014:148465

    PubMed  PubMed Central  Google Scholar 

  68. Tsivgoulis G, Triantafyllou N, Papageorgiou C, Evangelopoulos ME, Kararizou E, Sfagos C, Vassilopoulos D (2007) Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients. Acta Neurol Scand 115:67–72

    Article  CAS  PubMed  Google Scholar 

  69. Ayatollahi P, Nafissi S, Eshraghian MR, Kaviani H, Tarazi A (2007) Impact of depression and disability on quality of life in Iranian patients with multiple sclerosis. Mult Scler 13:275–277

    Article  CAS  PubMed  Google Scholar 

  70. Chwastiak LA, Ehde DM (2007) Psychiatric issues in multiple sclerosis. Psychiatr Clin N Am 30:803–817

    Article  Google Scholar 

  71. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klösch G, Kollegger H, Kristoferitsch W, Zeitlhofer J (2004) Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 110:6–13

    Article  CAS  PubMed  Google Scholar 

  72. Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret M, Vermersch P (2003) Multiple sclerosis and depression: influence of interferon beta therapy. Mult Scler 9:284–288

    Article  CAS  PubMed  Google Scholar 

  73. Levinthal DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K (2013) Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int 2013:319201

    PubMed  PubMed Central  Google Scholar 

  74. Maes M, Kubera M, Leunis JC (2008) The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 29:117–124

    PubMed  Google Scholar 

  75. Geffard M, Bodet D, Martinet Y, Dabadie MP (2002) Intérêt de l’évaluationd’IgM et d’IgA spécifiques circulant dans le sérum de malades atteints de sclérose en plaques (SEP). Immuno Anal Biol Spéc 17:302–310

    Google Scholar 

  76. Geffard M, Duleu S, Bessede A, Covenas R, Mangas A (2011) A new paradigm for multiple sclerosis. In: Geffard M (ed) Multiple sclerosis. A new paradigm. Nova Science Publishers 153–84

  77. Bodet D, Glaize G, Dabadie MP, Geffard M (2004) Suivi immunobiologique de malades atteints de Sclérose en Plaques. Immuno Anal Biol Spéc 19:138–147

    Google Scholar 

Download references

Acknowledgments

This study is supported by the Health Sciences Postgraduate Program at the State University of Londrina, Brazil; the Ministry for Sciences and Technology of Brazil (CNPq); and the Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES). MM is supported by a special CNPq (National Council of Scientific and Technology), PVE fellowship, and the Health Sciences Postgraduate Program fellowship, Londrina State University (UEL).

Conflict of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

All authors contributed equally to this paper.

Author information

Authors and Affiliations

  1. Health Sciences Postgraduate Program, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil

    Ana Paula Kallaur, Josiane Lopes & Michael Maes

  2. Department of Pathology, Clinical Analysis, and Toxicology, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil

    Sayonara Rangel Oliveira, Andrea Name Colado Simão, Edna Maria Vissoci Reiche, Elaine Regina Delicato de Almeida, Helena Kaminami Morimoto, Wildea Lice Carvalho Jennings de Pereira & Daniele Frizon Alfieri

  3. Department of Clinical Analysis, Laboratory of Immunogenetics, State University of Maringá, Maringá, Paraná, Brazil

    Sueli Donizete Borelli

  4. Outpatient Clinic for Multiple Sclerosis, University Hospital, State University of Londrina, Londrina, Paraná, Brazil

    Domacio Ramon Kaimen-Maciel

  5. Department of Clinical Medicine, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil

    Domacio Ramon Kaimen-Maciel

  6. Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand

    Michael Maes

  7. IMPACT Strategic Research Center, School of Medicine, Deakin University, PO Box 281, Geelong, 3220, Australia

    Michael Maes

Authors
  1. Ana Paula Kallaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josiane Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayonara Rangel Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Name Colado Simão
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edna Maria Vissoci Reiche
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elaine Regina Delicato de Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helena Kaminami Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wildea Lice Carvalho Jennings de Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniele Frizon Alfieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sueli Donizete Borelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Domacio Ramon Kaimen-Maciel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Michael Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Maes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kallaur, A.P., Lopes, J., Oliveira, S.R. et al. Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation. Mol Neurobiol 53, 5191–5202 (2016). https://doi.org/10.1007/s12035-015-9443-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-015-9443-4

Keywords

Search

Navigation